유전자 변형 치료 임상 응용 : 유전자 치료, 유전자 변형 세포치료, RNA 치료, 유전자 편집

The global market for genetic modification therapies is estimated to grow from $14.8 billion in 2025 to reach $32.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.8% from 2025 through 2030.

The North American market for genetic modification therapies is estimated to grow from $7.3 billion in 2025 to reach $16.4 billion by the end of 2030, at a CAGR of 17.7% from 2025 through 2030.

The European market for genetic modification therapies is estimated to grow from $4.1 billion in 2025 to reach $8.6 billion by the end of 2030, at a CAGR of 16.3% from 2025 through 2030.

Report Scope

The report provides an overview of genetic modification therapies clinical applications: gene therapies, genetically modified cell therapies, RNA therapies and gene editing market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. In this report, the market is segmented based on platform technology, application and region.

Based on platform technology, the market is segmented into gene editing, gene therapy, gene-modified cell therapy and RNA therapy platforms. The application segment covers oncology, rare diseases, cardiovascular diseases, musculoskeletal conditions, hematological disorders and other applications. The gene therapy segment is segmented based on the delivery systems into adeno-associated virus (AAV), herpes simplex virus (HSV)-1, lentivirus and others. The RNA therapy segment is segmented into antisense oligonucleotides, small interfering RNAs and others based on type.

The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, Asia-Pacific, and the Rest of the World, with a focus on major countries in these regions.

The report also includes major driving trends and restraints that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments, discussing pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also has a dedicated section of company profiles that covers details of leading companies. The report does not include mRNA vaccines.

Report Includes

• 103 data tables and 63 additional tables
• Overview and an analysis of the global market for clinical applications of genetic modification therapies
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the genetic modification therapies, accompanied by a market share analysis by platform technology, application and region
• Analysis of current and future demand in the genetic modification therapies, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Review of gene editing, gene therapy, CAR T-cell therapy, RNA therapy and lentiviral production, and discussion of how they are playing a key role in genetic modification therapies
• Analysis of drivers, challenges and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
• Profiles of the leading companies, including Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Novartis AG, Bristol-Myers Squibb Co., and Sarepta Therapeutics Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Porter's Five Forces Analysis
• Threat of New Entrants (Low)
• Bargaining Power of Suppliers (Moderate)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute (Low)
• Industry Rivalry (High)
• Macroeconomic Factors Analysis
• Impact of the U.S. Tariffs
• Geopolitical Factors

Chapter 3 Genetic Modification Therapies: Technology and Applications

• Genetic Modification Therapies
• Gene Therapy Technologies
• RNA Therapy Technologies
• Gene Editing Technologies
• Different Types of Genome Editing Tools
• Delivery Methods of Genome Editing
• Gene-Modified Cell Therapy Technologies
• Delivery Technologies
• Clinical Applications

Chapter 4 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Prevalence of Rare Genetic Disorders
• Growing Focus on Precision Medicine
• Market Restraints
• Regulatory Requirements on Adverse Event Tracking and Long-Term Monitoring
• Ethical Concerns on Genome Editing Techniques
• High Cost of Genetic Modification Therapies
• Market Opportunities
• Expanding Application Areas of Genetic Modification Therapies
• Off-the-Shelf Products in Gene-Modified Cell Therapies

Chapter 5 Emerging Technologies and Pipeline Analysis

• Key Takeaways
• Emerging Technologies
• In Vivo Delivery of CRISPR
• Improved Cas Variants
• Advances in RNAi Delivery Systems
• RNA Editing
• Pipeline Analysis
• RNA Therapies
• Gene Editing Therapies
• Gene Therapies and Gene-Modified Cell Therapies

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Platform Technology
• Key Takeaways
• RNA Therapy
• Gene-Modified Cell Therapy
• Gene Therapy
• Gene Editing
• Market Analysis by Application
• Key Takeaways
• Oncology
• Rare Diseases
• Cardiovascular Diseases
• Musculoskeletal Conditions
• Hematological Disorders
• Others
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Industry Structure
• Company Share Analysis of the RNA Therapies Market
• Company Share Analysis of the Gene Therapies Market
• Company Share Analysis of the Gene-Modified Cell Therapies Market
• Strategic Analysis

Chapter 8 Sustainability in the Genetic Modification Therapies Market: An ESG Perspective

• Introduction to ESG
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ALNYLAM PHARMACEUTICALS INC.
• AMGEN INC.
• BIOGEN
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• FERRING
• GENETIX BIOTHERAPEUTICS INC.
• GILEAD SCIENCES INC.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• NOVARTIS AG
• NOVO NORDISK A/S
• SANOFI
• SAREPTA THERAPEUTICS INC.
• VERTEX PHARMACEUTICALS INC.
• Emerging Startups/Market Disruptors